Regulation — pharma-specific
21st Century Cures Act §3013 — RWE + representative-population requirements
Section 3013 (and the FDA RWE Framework that operationalises it) sits behind FDA's ability to require post-marketing commitment trials (PMCs) when pre-approval representation gaps are found. AI-driven exclusion of a target subgroup is exactly the failure mode that surfaces this risk after approval.
What the statute + framework actually say
"The Secretary shall establish a program to evaluate the potential use of real world evidence … to help support the approval of a new indication for a drug … and to help support or satisfy postapproval study requirements."
21st Century Cures Act §3022 / Section 3013 supporting language on RWE + representative-population data (2016, implementation ongoing)
"FDA may require, at or after approval, one or more postmarketing studies … to assess a known serious risk related to the use of the drug involved … or to assess signals of serious risk related to use of the drug."
21 USC §355(o)(3) — PMC/PMR authority (frequently invoked when representation gaps become visible post-approval)
What this means in plain English
Two structural risks connected to AI-driven representation skew:
- Pre-approval question: if the pivotal trial's representation gap is discoverable post-approval, FDA can require a PMC trial to close the gap.
- Post-approval question: RWE data (claims, EHR, real-world registries) will eventually reveal underrepresented subgroup outcomes. If AI-driven exclusion caused the gap, the sponsor is on the hook for the follow-on cost.
PMC trial costs range widely, but public precedent typically puts them at $5M-$50M+ per program — without counting label-restriction risk.
What triggers the exposure in the sample
P3 exclusion is a Diversity-Plan-target subgroup exclusion. Post-approval, RWE will surface the outcomes in the excluded population. If those outcomes diverge from the pivotal-trial claims, FDA has statutory authority to require a PMC and can also revisit labelling. The Snapshot's dated evidence changes the sponsor's stance in that conversation.
What the $499 Snapshot shows against this rule
- Dated evidence the sponsor detected the representation gap in-trial — before RWE surfaced it post-approval
- 3 fix-first items that document the operational response — the "sponsor acted" record
- Independent-verifier signature — independence from the sponsor's own RWE partner
- Retention discipline documented for the FDA pivotal-trial 15-year horizon
Read the scenario that produces the exposure →
$499 Snapshot. 3 business days.
Independent-verifier determination scoped to your sponsor's AI surface + 3 fix-first items + signed declaration.
Buy $499
Snapshot credit applies to Baseline ($2,500) or Enterprise Attestation ($35-55K) upgrade within 30 days.